<bill session="114" type="h" number="3618" updated="2018-11-21T21:23:24Z">
  <state datetime="2015-09-25">REFERRED</state>
  <status>
    <introduced datetime="2015-09-25"/>
  </status>
  <introduced datetime="2015-09-25"/>
  <titles>
    <title type="short" as="introduced">Orphan Drug Fairness Act</title>
    <title type="official" as="introduced">To clarify the exclusion of orphan drug sales from the calculation of the annual fee on branded prescription pharmaceutical manufacturers and importers, and for other purposes.</title>
    <title type="display">Orphan Drug Fairness Act</title>
  </titles>
  <sponsor bioguide_id="L000567"/>
  <cosponsors>
    <cosponsor bioguide_id="B001273" joined="2015-10-01"/>
    <cosponsor bioguide_id="H001065" joined="2015-09-25"/>
    <cosponsor bioguide_id="M001158" joined="2015-10-21"/>
    <cosponsor bioguide_id="N000181" joined="2015-10-20"/>
    <cosponsor bioguide_id="P000096" joined="2015-09-25"/>
    <cosponsor bioguide_id="S001156" joined="2015-09-25"/>
    <cosponsor bioguide_id="T000462" joined="2015-09-25"/>
  </cosponsors>
  <actions>
    <action datetime="2015-09-25">
      <text>Introduced in House</text>
    </action>
    <action datetime="2015-09-25" state="REFERRED">
      <text>Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2015-09-25">
      <text>Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2015-10-02">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="" code="HSWM" name="House Ways and Means" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="114" relation="identical" number="1906"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Income tax credits"/>
    <term name="Prescription drugs"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2015-09-25T04:00:00Z" status="Introduced in House">Orphan Drug Fairness Act

This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.

This Act is effective as if included in PPACA.</summary>
  <committee-reports/>
</bill>
